SandboxAQ today announced a round of more than $300 million, which valued the company at $5.3 billion on a pre-money basis. The money came from investors Fred Alger Management, T Rowe Price Associates, Mumtalakat, Parkway Venture Capital, Breyer Capital, Rizvi Traverse, S32, US Innovative Technology Fund,… Read More
SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson’s disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson’s Research (MJFF) LRRK2 Investigative… Read More
OpenFold, a non-profit artificial intelligence (AI) research consortium focused on developing free and open-source software tools for biology and drug discovery, has added six new industry members. Joining the consortium are Astex Pharmaceuticals, Biogen, Congruence Therapeutics, Polaris Quantum Biotech, Psivant Therapeutics, and SandboxAQ. “This… Read More
Collaborators SandboxAQ and NVIDIA have reported a breakthrough that allows an 80-fold speed increase in computational chemistry calculations. SandboxAQ leverages Large Quantitative Models (LQMs) and the NVIDIA CUDA-accelerated Density Matrix Renormalization Group (DMRG) algorithm. Combining the CUDA-DMRG algorithm, the NVIDIA Quantum platform, and NVIDIA… Read More
SandboxAQ has acquired Good Chemistry, a computational chemistry company that leverages AI, quantum and other advanced technologies to accelerate drug discovery. Good Chemistry, which spun out of 1Qbit in 2021, is SandboxAQ’s second acquisition and its first in the AI simulation sector. “Good Chemistry’s… Read More
